Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) New York MDRU |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00015301 |
The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders Substance-Related Disorders |
Drug: Methylphenidate |
Phase IV |
Study Type: | Interventional |
Study Design: | Diagnostic, Double-Blind, Placebo Control |
Official Title: | Methylphenidate Raclopride PET Test |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Healthy normals
Exclusion Criteria:
History of head trauma or loss of consciousness. Significant medical history. History of seizures.
Study ID Numbers: | NIDA-5-0013-11, Y01-5-0013-11 |
Study First Received: | April 18, 2001 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00015301 |
Health Authority: | United States: Federal Government |
Cocaine-Related Disorders Dopamine Mental Disorders Raclopride |
Substance-Related Disorders Methylphenidate Disorders of Environmental Origin |
Dopamine Uptake Inhibitors Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Tranquilizing Agents Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants |
Dopamine Antagonists Central Nervous System Stimulants Antipsychotic Agents Pharmacologic Actions Pathologic Processes Therapeutic Uses Dopamine Agents Central Nervous System Agents |